Reducing TNT formation or stability through mTOR or CDC42 inhibition may be a useful therapeutic approach in cancer as well as in ageing, for example, through blocking the transfer of healthy mitochondria from bystander cells to rescue dysfunctional tumour cells, or through blocking the spread of drug resistance channels. The gene discussed is CDC42; the disease is cancer.